Citi cuts Teladoc price target to $8 from $8.75, keeps Buy rating

Published 01/05/2025, 10:40
Citi cuts Teladoc price target to $8 from $8.75, keeps Buy rating

On Thursday, Citi analyst Daniel Grosslight adjusted the price target on Teladoc Health Inc. (NYSE:TDOC) shares, bringing it down to $8.00 from the previous target of $8.75. Despite the reduction, the firm maintained a Buy rating on the stock. According to InvestingPro data, the stock currently trades at $7.19, with analyst targets ranging from $8 to $14, suggesting potential upside. The company’s market capitalization stands at $1.26 billion. Grosslight’s commentary highlighted a strong quarter for Teladoc, noting an increase in U.S. visits by 7% year-over-year, robust international growth with mid-teens constant currency (CC) growth, and an 8.7 million rise in membership. The company maintains a healthy gross profit margin of 70.76% and generated revenue of $2.57 billion in the last twelve months. InvestingPro analysis reveals 6 additional key insights about TDOC’s financial health and growth prospects, available to subscribers.

The analyst emphasized the significance of Teladoc’s recent $30 million acquisition of Uplift, a move expected to considerably enhance Behavioral Health’s (BH) capabilities in the insured market. According to Grosslight, this strategic acquisition places BH on a much more solid foundation. While operating with a moderate level of debt, the company maintains a solid current ratio of 1.77 and generated positive free cash flow of $283 million in the last twelve months. For deeper insights into TDOC’s financial position and growth potential, access the comprehensive Pro Research Report available on InvestingPro. He further explained that while guidance remained largely unchanged, there was a $15 million reduction in BH’s adjusted EBITDA forecast, which accounts for the costs associated with integrating Uplift, ranging between $10 million to $15 million. This adjustment also includes a conservative approach due to a weakening consumer environment, without which Teladoc would have reduced its BH revenue guidance by approximately $10 million.

The report suggests that the quarter’s performance indicates a positive trajectory for Teladoc, with expectations set for the company to return to growth in the following year. The acquisition of Uplift is seen as a key factor in this anticipated growth, as it is projected to significantly expand the company’s reach in the behavioral health segment within the insured market.

Teladoc Health Inc. is a multinational telemedicine and virtual healthcare company that offers a range of services including telehealth, medical opinions, AI and analytics, and licensable platform services. The company’s stock is traded on the New York Stock Exchange under the ticker symbol TDOC.

In other recent news, Teladoc Inc reported a first-quarter 2025 net loss per share of $0.53, missing analysts’ expectations of a $0.34 loss. Despite this, the company’s revenue of $629.4 million slightly exceeded forecasts of $619.33 million, showcasing strong operational performance. Teladoc has also made strategic moves by acquiring Uplift, a virtual mental health company, to bolster its BetterHelp segment. This acquisition aligns with Teladoc’s priority of expanding its virtual mental health services and leveraging BetterHelp’s extensive consumer base. Analysts have noted that the company maintains a robust cash position with nearly $1.2 billion in cash and equivalents. Furthermore, Teladoc reaffirmed its full-year 2025 revenue guidance, projecting between $2.47 billion to $2.58 billion. The company continues to expand its U.S. membership base, surpassing 100 million members, and is focusing on integrating recent acquisitions to enhance its service offerings. Despite challenges, Teladoc remains committed to its strategic priorities and exploring opportunities in international markets.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.